CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Compugen presents immuno-oncology pipeline update, targets COM701 interim analysis in Q1 2027

By Public Technologies
  • Compugen expects cash to fund operations into 2029, with a $117.5 million balance as of September 30, 2026.
  • An interim analysis of the COM701 MAIA-ovarian maintenance therapy trial is projected for the first quarter of 2027.
  • AstraZeneca's rilvegostomig program spans 12 Phase 3 trials, with ARTEMIDE-Biliary01 data anticipated in the second half of 2027.
  • Rilvegostomig could generate up to $195 million in additional milestone payments, with tiered royalties up to mid-single digits.
  • The GS-0321 licensing agreement with Gilead offers up to $758 million in additional milestones, with single-digit to low-double-digit tiered royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk